Mucosal immune response in biology, disease prevention and treatment DOI Creative Commons
Xiaoxue Zhou, Yuchen Wu,

Zhipeng Zhu

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2025, Номер 10(1)

Опубликована: Янв. 7, 2025

Abstract The mucosal immune system, as the most extensive peripheral network, serves frontline defense against a myriad of microbial and dietary antigens. It is crucial in preventing pathogen invasion establishing tolerance. A comprehensive understanding immunity essential for developing treatments that can effectively target diseases at their entry points, thereby minimizing overall impact on body. Despite its importance, our knowledge remains incomplete, necessitating further research. outbreak severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has underscored critical role disease prevention treatment. This systematic review focuses dynamic interactions between mucosa-associated lymphoid structures related diseases. We delve into basic functions these tissues during processes explore intricate regulatory networks mechanisms involved. Additionally, we summarize novel therapies clinical research advances immunity-related also addresses challenges vaccines, which aim to induce specific responses while maintaining tolerance non-pathogenic microbes. Innovative therapies, such nanoparticle vaccines inhalable antibodies, show promise enhancing offer potential improved

Язык: Английский

Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses DOI Creative Commons
Tianyang Mao, Benjamin Israelow,

Mario A. Peña-Hernández

и другие.

Science, Год журнала: 2022, Номер 378(6622)

Опубликована: Окт. 27, 2022

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has highlighted the need for vaccines that not only prevent disease but also transmission. Parenteral induce robust systemic immunity poor at mucosa. We developed a vaccine strategy we call "prime and spike," which leverages existing generated by primary vaccination (prime) to elicit mucosal immune memory within tract using unadjuvanted intranasal spike boosters (spike). show prime induces resident B T cell responses, immunoglobulin A mucosa, boosts immunity, completely protects mice with partial from lethal SARS-CoV-2 infection. Using divergent proteins, enables induction of cross-reactive against sarbecoviruses.

Язык: Английский

Процитировано

256
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages DOI Creative Commons
Young‐Jun Park, Dora Pinto, Alexandra C. Walls

и другие.

Science, Год журнала: 2022, Номер 378(6620), С. 619 - 627

Опубликована: Окт. 20, 2022

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry distinct spike mutations resulting in escape from antibodies induced by previous infection or vaccination. We show that hybrid immunity vaccine boosters elicit plasma-neutralizing against BA.1, BA.2, BA.2.12.1, and BA.4/5, breakthrough infections, but not vaccination alone, induce neutralizing the nasal mucosa. Consistent with immunological imprinting, most derived memory B cells plasma of cases cross-react Wuhan-Hu-1, BA.4/5 receptor-binding domains, whereas primary infections narrow specificity up to 6 months after infection. Although clinical have reduced neutralization Omicron, we identified an ultrapotent pan-variant–neutralizing antibody is a strong candidate for development.

Язык: Английский

Процитировано

207
Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses DOI Creative Commons
David M. Morens, Jeffery K. Taubenberger, Anthony S. Fauci

и другие.

Cell Host & Microbe, Год журнала: 2023, Номер 31(1), С. 146 - 157

Опубликована: Янв. 1, 2023

Язык: Английский

Процитировано

138
T Cell Responses to SARS-CoV-2 DOI
Alessandro Sette, John Sidney, Shane Crotty

и другие.

Annual Review of Immunology, Год журнала: 2023, Номер 41(1), С. 343 - 373

Опубликована: Фев. 8, 2023

A large body of evidence generated in the last two and a half years addresses roles T cells SARS-CoV-2 infection following vaccination. Infection or vaccination induces multi-epitope CD4 CD8 cell responses with polyfunctionality. Early have been associated mild COVID-19 outcomes. In concert animal model data, these results suggest that while antibody are key to prevent infection, may also play valuable reducing disease severity controlling infection. memory after is sustained for at least six months. While neutralizing impacted by variants, most preserved. This review highlights extensive progress made, data knowledge gaps remain, our understanding vaccines.

Язык: Английский

Процитировано

131
XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1 DOI Creative Commons
Qian Wang, Yicheng Guo, Anthony Bowen

и другие.

Cell Host & Microbe, Год журнала: 2024, Номер 32(3), С. 315 - 321.e3

Опубликована: Фев. 19, 2024

COVID-19 vaccines have recently been updated to specifically encode or contain the spike protein of SARS-CoV-2 XBB.1.5 subvariant, but their immunogenicity in humans has yet be fully evaluated and reported, particularly against emergent viruses that are rapidly expanding. We now report administration an monovalent mRNA vaccine booster (XBB.1.5 MV) previously uninfected individuals boosted serum virus-neutralizing antibodies significantly not only (27.0-fold increase) EG.5.1 (27.6-fold also key emerging such as HV.1, HK.3, JD.1.1, JN.1 (13.3- 27.4-fold increase). Individuals infected by Omicron subvariant had highest overall neutralizing titers (ID

Язык: Английский

Процитировано

116
SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and CD4+ T cells of broad specificity DOI Creative Commons
Joey Ming Er Lim, Anthony T. Tan, Nina Le Bert

и другие.

The Journal of Experimental Medicine, Год журнала: 2022, Номер 219(10)

Опубликована: Авг. 16, 2022

Rapid recognition of SARS-CoV-2-infected cells by resident T in the upper airway might provide an important layer protection against COVID-19. Whether parenteral SARS-CoV-2 vaccination or infection induces nasal-resident specific for distinct proteins is unknown. We isolated from nasal mucosa COVID-19 vaccinees who either experienced after (n = 34) not 16) and analyzed their phenotype, specificity, function, persistence. Nasal-resident SARS-CoV-2-specific CD8+ CD4+ were detected almost exclusively breakthrough infection. Importantly, Spike-specific primed did suppress induction other proteins. The cell responses persisted ≥140 d, with minimal sign waning. These data highlight importance viral challenge formation antiviral immunity at site primary further define immunological features hybrid immunity.

Язык: Английский

Процитировано

104
Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models DOI Creative Commons
Renee L. Hajnik, Jessica A. Plante, Yuejin Liang

и другие.

Science Translational Medicine, Год журнала: 2022, Номер 14(662)

Опубликована: Сен. 14, 2022

Emergence of SARS-CoV-2 variants concern (VOCs), including the highly transmissible Omicron and Delta strains, has posed constant challenges to current COVID-19 vaccines that principally target viral spike protein (S). Here, we report a nucleoside-modified messenger RNA (mRNA) vaccine expresses more conserved nucleoprotein (mRNA-N) show mRNA-N vaccination alone can induce modest control SARS-CoV-2. Critically, combining with clinically proven S-expressing mRNA (mRNA-S+N) induced robust protection against both variants. In hamster models VOC challenge, demonstrated that, compared mRNA-S alone, combination mRNA-S+N not only in lungs but also provided enhanced upper respiratory tract. vivo CD8

Язык: Английский

Процитировано

99
SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic DOI Creative Commons
Antonio Bertoletti, Nina Le Bert, Anthony T. Tan

и другие.

Immunity, Год журнала: 2022, Номер 55(10), С. 1764 - 1778

Опубликована: Авг. 18, 2022

Язык: Английский

Процитировано

98
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination DOI Creative Commons
Felicity Liew,

Shubha Talwar,

Andy Cross

и другие.

EBioMedicine, Год журнала: 2022, Номер 87, С. 104402 - 104402

Опубликована: Дек. 19, 2022

Язык: Английский

Процитировано

93
Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination DOI
Alexandra Suberi, Molly K. Grun, Tianyang Mao

и другие.

Science Translational Medicine, Год журнала: 2023, Номер 15(709)

Опубликована: Авг. 16, 2023

An inhalable platform for messenger RNA (mRNA) therapeutics would enable minimally invasive and lung-targeted delivery a host of pulmonary diseases. Development mRNA has been limited by poor transfection efficiency risk vehicle-induced pathology. Here, we report an polymer-based vehicle therapeutic mRNAs to the lung. We optimized biodegradable poly(amine- co -ester) (PACE) polyplexes using end-group modifications polyethylene glycol. These achieved high throughout lung, particularly in epithelial antigen-presenting cells. applied this technology develop mucosal vaccine severe acute respiratory syndrome coronavirus 2 found that intranasal vaccination with spike protein–encoding induced potent cellular humoral adaptive immunity protected susceptible mice from lethal viral challenge. Together, these results demonstrate translational potential PACE lungs.

Язык: Английский

Процитировано

87